Breath Biopsies: A Revolutionary Approach for Noninvasive Diagnosis
This report assesses the latest developments in breath biopsy research and analysis and explores the novel approaches that companies are adopting to identify and enhance breath biopsy in drug development, diagnosis and treatment of respiratory diseases, cancer, metabolic disorders and CNS diseases.
- Detailed discussion on breath as a snapshot of an individuals’ health
- Assessment of the role of breath biopsy in drug development, diagnosis and treatment of respiratory diseases, cancer, metabolic disorders and CNS diseases
- Discussion about proton‐transfer‐reaction time‐ of‐flight mass spectrometry (PTR‐ToF‐MS), gas chromatography time-of-flight mass spectrometers (GC-TOF-MS) and field asymmetric ion mobility spectrometry (FAIMS)
- Coverage of latest developments in breath biopsy research & analysis and strategies adopted by institutes and start-up companies to identify and enhance breath biopsy in drug development
Dr. C.L. Barton has more than 10 years of practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C.L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patient- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.